Current Insights of BRAF Inhibitors in Cancer.

Abstract excerpt

Oncogenic BRAF kinase deregulates the ERK signaling pathway in a large number of human tumors. FDA-approved BRAF inhibitors for BRAFV600E/K tumors have provided impressive clinical responses extending survival of melanoma patients. However, these drugs display paradoxical activation in normal tissue with BRAFWT due to RAF transactivation and priming, acquired drug resistance, and limited clinical effectiveness in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Discovery
• Share to BRAF gene
• Share to Mutation